Phio Pharmaceuticals Corp. (PHIO)
| Market Cap | 12.55M +5.3% |
| Revenue (ttm) | n/a |
| Net Income | -12.90M |
| EPS | -1.36 |
| Shares Out | 11.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,606 |
| Open | 1.100 |
| Previous Close | 1.110 |
| Day's Range | 1.075 - 1.125 |
| 52-Week Range | 0.813 - 4.190 |
| Beta | 0.79 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About PHIO
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name... [Read more]
Financial Performance
Financial StatementsNews
Phio Pharmaceuticals Proxy statement: Proxy filing
Phio Pharmaceuticals filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Phio Pharmaceuticals Proxy statement: Proxy filing
Phio Pharmaceuticals filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements...
Phio Pharmaceuticals Quarterly report: Q2 2026
Phio Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Phio Pharmaceuticals Earnings release: Q2 2026
Phio Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopha...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA bioph...
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Brings extensive experience in patient care, dermatologic research and commercialization King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is ...
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ...
Phio Pharmaceuticals Slides: Corporate presentation
Phio Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Phio Pharmaceuticals Transcript: Fireside chat
The discussion highlighted the successful phase Ib results for PH-762, the unique and versatile INTASYL platform, and the company's proactive approach to manufacturing and regulatory compliance. Plans are in place for a phase II trial next year, with a likely capital raise to support further development.
Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum
INTASYL technology enables precise, safe gene silencing for cancer immunotherapy, with PH-762 showing strong safety and efficacy in phase I-B trials for cutaneous squamous cell carcinoma. Commercial-scale production and a robust pipeline support future growth, with significant market potential and broad clinical applicability.
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manufactured supply will support upcoming clinical trial in next development phase King of Prussia, Penn...
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology Data Key Development Agreements Secured for Nonclinical Toxicology a...
Phio Pharmaceuticals Quarterly report: Q1 2026
Phio Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Phio Pharmaceuticals Earnings release: Q1 2026
Phio Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Phio Pharmaceuticals Transcript: Fireside chat
The discussion highlighted a novel siRNA-based therapy for skin cancer that targets PD-1 locally, showing promising safety and efficacy in early trials. The technology could reduce the need for invasive surgery and has potential applications in other cancers, with regulatory milestones and funding strategies outlined for the next year.
Phio Pharmaceuticals Transcript: Second Annual Centri Capital Conference
A novel RNA-based immunotherapy for skin cancer showed strong efficacy and safety in phase I-B trials, with plans to advance to phase II-B/III next year. The company is well-capitalized, focusing on high-value indications and out-licensing non-core assets.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event R. Todd Plott, M.D.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous Carcinomas King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a ...
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT) King of Prussia, Pennsylvania--(Newsfile Corp. - Ma...
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to ...
Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum
A novel RNA-based therapy for skin cancer demonstrated strong efficacy and safety in early trials, with 85% response at the highest dose and no toxicities. The company is preparing for pivotal studies, has a robust IP portfolio, and is exploring partnerships for broader applications.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...